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Dear Sir,
Cutaneous melanoma is the most aggressive form of skin cancer and several families of
receptor tyrosine kinases have been implicated in its development and progression,
including the Eph receptor family (Hess et al., 2007; Smalley et al., 2009). Among Eph
receptors, EphA2 has been most extensively studied in melanoma and linked to increased
malignancy (Hess et al., 2007; Margaryan et al., 2009). The roles of other Eph receptors in
melanoma progression, however, have not been extensively characterized. A recent study
has shown that overexpression of EphB4 in murine B16 melanoma cells (which do not
express the preferred EphB4 ligand, ephrin-B2) decreases the survival of ephrin-B2-positive
tumor endothelial cells, suggesting that EphB4 may function as a tumor suppressor in
melanoma by inhibiting angiogenesis (Huang et al., 2007). However, the widespread
expression EphB4 in human cancers (Pasquale, 2010), including melanomas (Figure S1),
suggests a possible positive role in tumor progression.
Our previous work showed that EphB4 promotes the migratory ability of a series of murine
melanoma cell lines (Yang et al., 2006). SW1 and C19 represent distinctive clones derived
from the same parental cell line. The more aggressive SW1 cells express high levels of
EphB4 and have high migratory ability, whereas the less aggressive C19 cells have low
EphB4 levels and migrate poorly. The two cell lines similarly express the ephrin-B2 ligand.
We previously reported that EphB4 endogenously co-expressed with ephrin-B2 in SW1 cells
or transiently transfected in C19 cells promotes cell migration in vitro by activating the
RhoA GTPase, thus inducing actin cytoskeleton reorganization. Here we show that EphB4
co-expression with ephrin-B2 also promotes SW1 and C19 cell growth in vitro and tumor
growth in vivo.
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We generated 4 stable C19 clones overexpressing EphB4 (C19-EphB4) as well as SW1 and
C19 clones expressing EGFP (SW1 and C19; Figures 1A and S2A) and examined their
proliferation by measuring BrdU incorporation and apoptosis by Hoechst nuclear staining.
SW1 cells, which express high levels of endogenous EphB4, proliferate faster and exhibit
less apoptosis compared to C19 cells. The C19-EphB4 clones, where the transfected EphB4
is expressed at levels similar to those in the SW1 clones, have proliferation and apoptotic
rates comparable to the SW1 cells (Figures 1B,C and S2B,C). These results show that
coexpression of EphB4 with ephrin-B2 promotes melanoma cell proliferation and survival in
vitro. To investigate the in vivo role of EphB4 in melanoma growth, we used the stable
clones to generate tumors in a mouse xenograft model. The SW1 and C19-EphB4 tumors
grew faster than the C19 tumors over a period of 4.7 weeks, while there was no significant
difference in body weight between the 3 groups of mice (Figure S2D). Enhancement of
melanoma tumor growth by EphB4 was confirmed by injecting a mixture of 3 additional
SW1, C19 or C19-EphB4 clones and measuring tumor growth for 7.5 weeks (Figure 1D).
Several lung metastases were observed at 7.5 weeks in the mice bearing SW1 tumors, but
not in the ones with either C19 or C19-EphB4 tumors (data not shown), suggesting that high
EphB4 expression alone may not be sufficient to promote the formation of detectable
metastases.
To investigate the signaling pathways that promote the growth of melanoma cells expressing
high EphB4 levels, we first assessed EphB4 tyrosine phosphorylation as an indication of
receptor activation. This revealed that EphB4 is substantially activated in the SW1 and C19-
EphB4 tumors (Figure 2A), consistent with the reported expression of the ephrin-B2 ligand
in both SW1 and C19 cells and the extensive cell-cell contacts present in the 3-dimensional
tumor environment (Yang et al., 2006). We then examined the effects of EphB4 expression
on the activation of the Erk1/2 and the Akt kinases, which are known to play a critical role
in melanoma cell transformation, survival and proliferation (Gray-Schopfer et al., 2007;
Lopez-Bergami et al., 2008). We detected significantly higher levels of Erk1/2
phosphorylation at threonine 202 and tyrosine 204 and Akt phosphorylation at serine 473 in
SW1 and C19-EphB4 tumors compared to C19 tumors, indicating increased activation of
Erk1/2 and Akt (Figure 2B,C). We also detected higher levels of the anti-apoptotic protein
Bcl-2 in the SW1 and C19-EphB4 tumors than the C19 tumors (Figure 2D). The higher
Erk1/2 and Akt activity (which are consistent with the EphB4-dependent activation of Akt
previously observed in breast cancer and endothelial cells (Steinle et al., 2002; Kumar et al.,
2006)) and the higher Bcl-2 expression, would all be expected to contribute to the faster
growth of tumors expressing activated EphB4.
Besides cell proliferation and apoptosis, angiogenesis is another important event that
contributes to tumor progression. Given that EphB4 can activate reverse signaling through
ephrin-B2 on adjacent endothelial cells to promote angiogenesis and blood vessel
remodeling (Pasquale, 2010), we also examined the effects of EphB4 on tumor
vascularization. Quantitative analysis of CD31-stained tumor sections revealed that the
blood vessels were significantly larger in both SW1 and C19-EphB4 tumors than in C19
tumors at both 4.7 weeks and 7.5 weeks (Figures 2E and S3A). No significant difference
was observed in blood vessel densities between the 3 groups, although more blood vessels
were formed over the same time period in the tumors expressing EphB4, given the larger
size of these tumors. To verify that the vascular differences observed were not due to the
different tumor sizes, we also examined tumors of similar size, which were collected at
different times after melanoma cell injection. SW1 and C19-EphB4 tumors similar in size to
the C19 tumors also had larger blood vessels (Fig. S3B). These data suggest that EphB4
expression causes blood vessel growth and enlargement in SW1 and C19-EphB4 melanoma
tumors. If increased vascularization in EphB4-expressing tumors supports faster growth of
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tumor cells, this would result in larger tumors with similar vascular densities (Kerbel and
Folkman, 2002).
Although EphB4 promotes SW1 and C19 melanoma cell malignancy, this receptor has been
reported to suppress tumorigenicity in breast and colorectal cancer cells (Pasquale, 2010).
These divergent activities may depend in part on whether the ephrin-B2 ligand is co-
expressed and persistently activates the receptor and on other contextual factors. In addition,
ephrin-B2 can also transduce signals through its cytoplasmic domain, which are known as
reverse signals and are triggered by binding to Eph receptors (Pasquale, 2010; Meyer et al.,
2005). Since both EphB4 and ephrin-B2 are present in SW1 and C19-EphB4 cells, we
cannot exclude that some of the tumor promoting effects observed could be due to ephrin-
B2 reverse signaling.
In conclusion, we show that besides promoting RhoA-dependent migration (Yang et al.,
2006), EphB4 can promote the growth of melanomas expressing the ephrin-B2 ligand by
stimulating proliferation, survival and angiogenesis. Our findings suggest that upregulation
of EphB4 receptor expression can play a role in melanoma progression, particularly in
tumors where Erk and/or Akt are not highly activated by mutations.
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EphB4 promotes melanoma cell proliferation and inhibits apoptosis in vitro and promotes
melanoma tumor growth in vivo. (A) EphB4 expression levels in 3 SW1, C19 and C19-
EphB4 clones (data for clone #1 are shown in Figure S2). Lysates were probed by
immunoblotting for EphB4, and GAPDH as a loading control. (B) Cell proliferation
assessed by measuring BrdU incorporation. The histograms show average percentages of
BrdU-positive cells 2 hours following BrdU application ± SEM (n ~1,000 cells per group
from 3 independent experiments; ***p < 0.001 compared with the C19 cells by one-way
ANOVA). (C) Apoptosis assessed by Hoechst 33342 staining. The histograms show average
percentages of Hoechst-positive cells ± SEM (n ~2,250 cells per group from 3 independent
experiments; ***p < 0.001 compared with the C19 cells by one-way ANOVA). (D)
Photographs of representative 7.5 week-old tumors derived from a mixture of 3 clones (#2,
#3 and #4) of SW1, C19 or C19-EphB4 cells. The growth curves show average tumor
volumes ± SEM measured at the indicated times in groups of 6 mice. **p < 0.01 compared
with the C19 group using repeated measures two-way ANOVA. The histograms show
average tumor weights and body weights ± SEM measured at 7.5 weeks (n = 6 tumors per
group; **p < 0.01 compared with the C19 group by one-way ANOVA).
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EphB4 upregulates Erk and Akt phosphorylation and Bcl-2 expression, and promotes blood
vessel enlargement in melanoma tumors. (A) EphB4 immunoprecipitates from tumors
grown for 7.5 weeks were probed for phosphotyrosine (pTyr) and reprobed for EphB4. The
histogram shows average levels of phosphorylated EphB4 quantified by densitometry and
normalized to total EphB4 ± SEM (n = 4 tumors per group; ***p < 0.001 compared with the
C19 tumors by one-way ANOVA). (B, C, D) Tumor lysates were probed for phosphoErk1/2
Thr202/Tyr204 and total Erk1/2, phosphoAkt S473 and total Akt, Bcl-2 and GAPDH. The
histograms show the average levels of pErk, pAkt or Bcl-2 quantified by densitometry and
normalized to total Erk, total Akt or GAPDH ± SEM (n = 4 tumors per group; *p < 0.05;
**p < 0.01; ***p < 0.001 compared with the C19 tumors by one-way ANOVA). The lanes
in each blot are from the same gel and the white space indicates that an irrelevant lane
between the SW1 and C19 lanes was removed. (E) Fluorescent images of EGFP-positive
melanoma cells (green) and blood vessels stained with anti-CD31 antibody (red) in frozen
sections from tumors collected at 7.5 weeks. The histograms show average areas occupied
by blood vessels and number of blood vessels per image (image area 180 mm2). Scale bar, 2
µm. The histograms show averages ± SEM (n = 16 sections from 3–4 mice corresponding to
~1,000 blood vessels per group; *p < 0.05; **p < 0.01; ***p < 0.001 compared to C19
tumors by one-way ANOVA).
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